Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

被引：0
|
作者：
Herbst, R. S. [1 ]
Martin-Liberal, J. [2 ]
Calvo, E. [3 ]
Isambert, N. [4 ]
Bendell, J. [5 ]
Cassier, P. [6 ,7 ]
Jin, J. [8 ]
Mi, G. [9 ]
Rege, J. [8 ]
Paz-Ares, L. [10 ]
机构：
[1] Yale Univ, Sch Med, Med Oncol, New Haven, CT USA
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] START Madrid HM CIOCC, Ctr Integral Oncol Clara Campal, Early Clin Drug Dev Program, Madrid, Spain
[4] Ctr Georges Francois Leclerc Dijon, Dijon, France
[5] Sarah Cannon Res Inst Tennessee Oncol, Nashville, TN USA
[6] Ctr Leon Berard, Lyon, France
[7] Claude Bernard Univ, Lyon, France
[8] Eli Lilly & Co, Bridgewater, NJ USA
[9] Eli Lilly & Co, Indianapolis, IN 46285 USA
[10] Virgen del Rocio Univ Hosp, Seville, Spain
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
90PD
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Safety and efficacy of ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: a multi-disease phase 1 study
    Thuss-Patience, P.
    Vasile, E.
    Chau, I
    Penel, N.
    Mi, G.
    Emig, M.
    Fuchs, C. S.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 254 - 255
  • [2] Ramucirumab plus pembrolizumab in previously treated advanced or metastatic biliary tract cancer: A multi-disease phase 1 study
    Hendrik-Tobias, Arkenau
    Johanna, Bendell
    Roy, Herbst
    Gu, Mi
    Jin, Jin
    Jessicca, Rege
    David, Ferry
    Ian, Chau
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [3] Interim safety and clinical activity in patients with advanced NSCLC from a multi-cohort phase 1 study of ramucirumab (R) plus pembrolizumab (P)
    Herbst, R. S.
    Martin-Liberal, J.
    Calvo, E.
    Isambert, N.
    Bendell, J. C.
    Cassier, P.
    Perez-Gracia, J. L.
    Yang, J.
    Rege, J.
    Mi, G.
    Ferry, D.
    Paz-Ares, L.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [4] Ramucirumab (R) plus pembrolizumab (P) in treatment naive and previously treated advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: A multi-disease phase I study.
    Chau, Ian
    Bendell, Johanna C.
    Calvo, Emiliano
    -Davila, Rafael Santana
    Arkenau, Hendrik-Tobias
    Mi, Gu
    Jin, Jin
    Rege, Jessicca
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
    Herbst, Roy S.
    Arkenau, Hendrik Tobias
    Bendell, Johanna
    Arrowsmith, Edward
    Wermke, Martin
    Soriano, Andres
    Penel, Nicolas
    Santana-Davila, Rafael
    Bischoff, Helge
    Chau, Ian
    Mi, Gu
    Wang, Hong
    Rasmussen, Erik
    Ferry, David
    Chao, Bo H.
    Paz-Ares, Luis
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (02) : 289 - 298
  • [6] Phase 2 Study of Pembrolizumab Plus CC-486 vs Pembrolizumab Plus Placebo in Previously Treated Patients with Advanced NSCLC
    Levy, B.
    Giaccone, G.
    Besse, B.
    Felip, E.
    Garassino, M.
    Domine, M.
    Garrido, P.
    Piperdi, B.
    Ponce Aix, S.
    Slepetis, R.
    Wu, X.
    Fandi, A.
    Paz-Ares, L.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1803 - S1804
  • [7] Safety and antitumor activity of ramucirumab plus pembrolizumab in treatment naive advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: Preliminary results from a multi-disease phase I study (JVDF)
    Chau, Ian
    Penel, Nicolas
    Arkenau, Hendrik-Tobias
    Santana-Davila, Rafael
    Calvo, Emiliano
    Soriano, Andres O.
    Mi, Gu
    Jin, Jin
    Ferry, David
    Herbst, Roy S.
    Fuchs, Charles S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [8] Ramucirumab plus merestinib in previously treated metastatic colorectal cancer safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study
    Saleh, M.
    Cassier, P.
    Eberst, L.
    Naik, G.
    Morris, V., II
    Pant, S.
    Terret, C.
    Gao, L.
    Long, A.
    Mao, H.
    McNeely, S.
    Carlesi, R.
    Fu, S.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [9] A phase 1/2 study of ramucirumab plus nivolumab in patients with previously treated advanced gastric adenocarcinoma
    Shoji, H.
    Miyamoto, H.
    Hara, H.
    Takahari, D.
    Machida, N.
    Esaki, T.
    Nagashima, K.
    Aoki, K.
    Honda, K.
    Nagata, Y.
    Miyamoto, T.
    Boku, N.
    Kato, K.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] Efficacy and safety of anti-PD-1 therapy plus anlotinib in previously treated advanced NSCLC
    Lv, X.
    Wang, L.
    Su, S.
    Li, R.
    Liu, B.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1009 - S1009
12345